BLACK DIAMOND THERAPEUTICS INC. - COMMON STOCK

2,2550

11-февраля-25 08:52:32

15 мин. задержка

Акции

+0,0250

+1,12%

Сегодняшний диапазон

2,1850 - 2,2550

ISIN

N/A

Источник

NASDAQ

Black Diamond Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

05 янв 2022 07:00:02 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences

08 ноя 2021 15:05:02 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update

08 ноя 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Presents Preclinical Data on BDTX-1535, BRAF, and FGFR Programs at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

08 окт 2021 15:05:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-1535, BRAF, and FGFR Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

30 сен 2021 15:35:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at the 2021 Cantor Fitzgerald Virtual Global Healthcare Conference

21 сен 2021 15:05:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics and OpenEye Scientific Announce Collaboration to Expand MAP Drug Discovery Platform

21 сен 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate Update

12 авг 2021 07:22:20 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Announces Appointment of Mark Velleca, M.D., Ph.D. to Board of Directors

10 авг 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences

04 авг 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Presents Phase 1 Pharmacokinetic, Safety, and Preliminary Efficacy Data of BDTX-189 in Advanced Solid Tumors Harboring EGFR or HER2 Alterations

19 май 2021 16:00:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Host Webcast Presentation of Data From Phase 1 Dose-Escalation Portion of MasterKey-01 Clinical Trial

17 май 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate Update

07 май 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present Phase 1 BDTX-189 Data in Advanced Solid Tumors at American Society of Clinical Oncology

28 апр 2021 09:38:27 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Announces Preclinical Data Presentations on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

10 апр 2021 07:30:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update

25 мар 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present Pre-Clinical Data on BDTX-189 and BDTX-1535 at American Association for Cancer Research Annual Meeting

10 мар 2021 15:58:50 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics Announces Pre-Clinical Data Presentations on New Programs Targeting BRAF and FGFR at ESMO TAT Virtual Congress 2021

02 мар 2021 15:05:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at Upcoming Investor Conferences

23 фев 2021 06:45:00 Источник Nasdaq GlobeNewswire
Black Diamond Therapeutics to Present at the BMO Biopharma Spotlight Series

11 фев 2021 15:15:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.